Greenwood Capital Associates’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Greenwood Capital Associates’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,583	Closed	-$443K	–	234
2022 Q3	$443K	Buy	+5,583	New	+$471K	0.08%	187
2021 Q4	–	Sell	-4,572	Closed	-$575K	–	231
2021 Q3	$575K	Sell	4,572 -784	-15%	-$101K	0.09%	175
2021 Q2	$725K	Buy	+5,356	New	+$704K	0.11%	146
2021 Q1	–	Sell	-5,782	Closed	-$814K	–	236
2020 Q4	$814K	Buy	+5,782	New	+$741K	0.14%	126
2020 Q2	–	Sell	-24,403	Closed	-$1.89M	–	201
2020 Q1	$1.89M	Buy	+24,403	New	+$2.16M	0.55%	54
2018 Q3	–	Sell	-29,567	Closed	-$2.81M	–	224
2018 Q2	$2.81M	Buy	+29,567	New	+$2.72M	0.65%	62
2018 Q1	–	Sell	-3,391	Closed	-$288K	–	230
2017 Q4	$288K	Sell	3,391 -294	-8%	-$24.6K	0.07%	156
2017 Q3	$319K	Buy	+3,685	New	+$295K	0.08%	140

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Greenwood Capital Associates's XBI Position: Q4 2022 in Review

Greenwood Capital Associates sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2022, closing a stake of 5,583 shares — an estimated $443K sold.

Greenwood Capital Associates first reported a position in XBI in Q3 2017 and held it in 8 quarters. The position peaked at $2.81M in Q2 2018. 746 funds tracked by Wall St. Rank hold XBI as of Q4 2022.

Greenwood Capital Associates reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2022 after selling out during the quarter.
Greenwood Capital Associates sold 5,583 State Street SPDR S&P Biotech ETF shares in Q4 2022, an estimated $443K.
Greenwood Capital Associates first reported a position in State Street SPDR S&P Biotech ETF in Q3 2017 and held it in 8 quarters.
Greenwood Capital Associates's State Street SPDR S&P Biotech ETF position peaked at $2.81M in Q2 2018.
746 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2022.

Based on Greenwood Capital Associates's 13F filing for Q4 2022, filed 26 Jan 2023.